Medifast director Parsa Kiai buys 72K shares
MEDIFAST INC (MED) director Parsa Kiai reported indirect open-market purchases of MED common stock on August 19–20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MEDIFAST INC (MED) director Parsa Kiai reported indirect open-market purchases of MED common stock on August 19–20, 2026. Entities associated with him bought a total of 72,487 shares at weighted-average prices of $11.6576 and $11.6037 per share. The positions are held by Steamboat Capital funds, over which affiliated entities have investment discretion. Kiai may be deemed to have a pecuniary interest in these shares but disclaims beneficial ownership except to that extent. The trades were not reported as made under a Rule 10b5-1 trading plan.
Insights
Analyzing...
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1, F3, F5 | 41,975 | $11.6037 | $487K |
| Purchase | Common Stock F2, F3, F5 | 1,175 | $11.6037 | $14K |
| Purchase | Common Stock F1, F3, F4 | 28,538 | $11.6576 | $333K |
| Purchase | Common Stock F2, F3, F4 | 799 | $11.6576 | $9K |
Footnotes (5)
- F1. Ownership of Steamboat Capital Partners Master Fund, LP (Master) which has delegated investment discretion to Steamboat Capital Partners, LLC (IA).
- F2. Ownership of Steamboat Capital Partners II, LP (II).
- F3. Steamboat Capital Partners GP, LLC (GP) is general partner of, and entitled to receive a performance allocation from, each of Master and II. Parsa Kiai ("Kiai") is the Managing Member of GP and IA. Accordingly, Kiai may be deemed to have a pecuniary interest in the shares owned by Master and II. Kiai disclaims beneficial ownership of securities reported hereon except to the extent of his pecuniary interest therein.
- F4. This is an average price. Actual prices paid for the shares purchased on 8/19/26 and reported on this line range from $11.56 to $11.80. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This is an average price. Actual prices paid for the shares purchased on 8/20/26 and reported on this line range from $11.46 to $11.77. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
investment discretion financial
performance allocation financial
pecuniary interest financial
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did MED (MEDIFAST INC) disclose in this Form 4?
Were the MED insider purchases made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.